Michael Ahlijanian

Michael Ahlijanian, Ph.D., joined Pinteon as chief scientific officer in June 2017. Previously, he was the director of genetically defined disease biology and head of clinical biomarkers at Bristol-Myers Squibb. In this role, he led scientific discovery teams that produced clinical candidates for large and small molecule therapeutics for neurologic and muscle-wasting diseases. He also led the preclinical and clinical implementation and analysis of translational biomarkers for these assets. Michael also held previous senior management roles as head of neuroscience at FORMA Therapeutics, vice president of research at EnVivo Pharmaceuticals and executive director of neuroscience operations at Pfizer. He is a recognized leader in the development of novel therapeutics for central nervous system diseases and accomplished in promoting cultural change in research organizations. Michael received his Ph.D. in 1985 from the University of Minnesota Department of Pharmacology and a bachelor’s degree in pharmacy with distinction at the University of Rhode Island.